Connor, Clark & Lunn Investment Management Ltd.
Position in ZYME — Zymeworks Inc.
CIK 1596800
VANCOUVER, A1
Position in ZYME
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$949,491
-$703,853 QoQ
Shares Held
37,919
-60.8% QoQ
Ownership
0.052%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2023
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Connor, Clark & Lunn Investment Management Ltd. holds $703,286,486 across 100 Biotechnology names. ZYME ranks #70 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
251,711 | $112,399,029 | |
| 2 | IONS |
Ionis Pharmaceuticals Inc
|
874,089 | $65,635,343 | |
| 3 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
836,981 | $52,478,708 | |
| 4 | MIRM |
Mirum Pharmaceuticals, Inc.
|
479,476 | $44,293,992 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
32,164 | $24,851,192 | |
| 6 | AXSM |
Axsome Therapeutics, Inc.
|
134,792 | $22,782,543 | |
| 7 | SRPT |
Sarepta Therapeutics, Inc.
|
1,019,951 | $22,194,133 | |
| 8 | TERN |
Terns Pharmaceuticals, Inc.
|
384,681 | $20,280,382 |
All Filings in ZYME
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $949,491 | 37,919 | Shares | Sole | 2026-05-11 | |
| 2025-09-30 | $1,653,344 | 96,800 | Shares | Sole | 2025-11-13 | |
| 2024-03-31 | $848,974 | 80,701 | Shares | Sole | 2024-05-09 | |
| 2023-12-31 | $856,904 | 82,474 | Shares | Sole | 2024-02-09 | |
| 2023-09-30 | $113,625 | 17,922 | Shares | Sole | 2023-11-13 | |
| 2023-06-30 | $491,209 | 56,853 | Shares | Sole | 2023-08-10 | |
| 2023-03-31 | $373,388 | 41,304 | Shares | Sole | 2023-05-10 | |
| No filing history on record for this holder in this stock. | ||||||